参考文献/References:
[1] Henderson RA. Acute coronary syndrome: optimising management through risk assessment[J]. Clin Med,2013,13:602-606.
[2] Scirica BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment[J]. J Am Coll Cardiol,2010,55:1403-1415.
[3] Jacobs DR Jr, Kroenke C, Crow R, et al. PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey[J]. Circulation,1999,100:599-607.
[4] Killip T Ⅲ, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients[J]. Am J Cardiol,1967,20:457-464.
[5] Morrow DA, Antman EM, Charlesworth A, et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early Ⅱ Trial Substudy[J]. Circulation,2000,102:2031-2037.
[6] Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making[J]. JAMA,2000,284:835-842.
[7] Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction[J]. Circulation,1995,91:1659-1668.
[8] Hillis LD, Forman S, Braunwald E. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction: the Thrombolysis in Myocardial Infarction(TIMI)Phase Ⅱ co-investigators[J]. J Am Coll Cardiol, 1990,16:313-315.
[9] The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein Ⅱb/Ⅲa with eptifibatide in patients with acute coronary syndromes[J]. N Engl J Med,1998,339:436-443.
[10] Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST segment elevation: results from an international trial of 9,461 patients. The PURSUIT Investigators[J]. Circulation,2000,101:2557-2567.
[11] Brilakis ES, Wright RS, Kopecky SL, et al. Association of the PURSUIT risk score with predischarge ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction[J]. Am Heart J,2003,146:811-818.
[12] Dorsch MF, Lawrance RA, Sapsford RJ, et al. A simple benchmark for evaluating quality of care of patients following acute myocardial infarction[J]. Heart,2001,86:150-154.
[13] Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME Ⅱ substudy[J]. Lancet,2001,358:1571-1575.
[14] Gale CP, Manda SO, Weston CF, et al. Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction National Audit Project(MINAP)database[J]. Heart,2009,95:221-227.
[15] Piombo AC, Gagliardi JA, Guetta J, et al. A new scoring system to stratify risk in unstable angina[J]. BMC Cardiovasc Disord,2003,3:8.
[16] Dudek D, Siudak Z, Kuta M, et al. Management of myocardial infarction with ST segment elevation in district hospitals without catheterisation laboratory—Acute Coronary Syndromes Registry of Malopolska 2002-2003[J]. Kardiol Pol, 2006, 64:1053-1060.
[17] Dziewierz A, Siudak Z, Rakowski T, et al. More aggressive pharmacological treatment may improve clinical outcome in patients with non-ST-elevation acute coronary syndromes treated conservatively[J].Coron Artery Dis,2007,18:299-303.
[18] Kurz DJ, Bernstein A, Hunt K, et al. Simple point-of-care risk stratification in acute coronary syndromes: the AMIS model[J]. Heart,2009,95:662-668.
[19] Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events[J]. Arch Intern Med,2003,163:2345-2353.
[20] Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study(GRACE)[J]. BMJ,2006,333:1091-1094.
[21] Fox KAA, Eagle KA, Gore JM, et al. The Global Registry of Acute Coronary Events, 1999 to 2009-GRACE[J]. Heart,2010,96:1095-1101.
[22] Yan AT, Yan RT, Tan M, et al. Risk scores for risk stratification in acute coronary syndromes:useful but simpler is not necessarily better[J]. Eur Heart J,2007,28:1072-1078.
[23] Harris PR, Stein PK, Fung GL, et al. Prognostic value of heart rate turbulence for risk assessment in patients with unstable angina and non-ST elevation myocardial infarction[J]. Vasc Health Risk Manag,2013,9:465-473.
[24] Jansson AM, Hartford M, Omland T, et al. Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes[J]. Arterioscler Thromb Vasc Biol,2012,32:3041-3049.
[25] 高展,乔树宾. 冠状动脉左主干及三支病变的血运重建策略SYNTAX研究解析[J]. 中华心血管病杂志,2010,38:76-79.
[26] Wsek W, Maciejewski P, Toruń A, et al. Can we improve the accuracy of risk assessment in patients with non ST-segment elevation acute coronary syndromes? [J]. Kardiol Pol,2013,71:803-809.
[27] Zheng Z, Li Y, Zhang S, et al.The Chinese coronary artery bypass grafting registry study: how well does the EuroSCORE predict operative risk for Chinese population? [J]. Eur J Cardiothorac Surg,2009,35:54-58.
[28] Granger CB, Steg PG, Peterson E, et al. Medication performance measures and mortality following acute coronary syndromes[J]. Am J Med,2005,118:858-865.
[29] Chew DP, Juergens C, French J, et al. An examination of clinical intuition in risk assessment among acute coronary syndromes patients: observations from a prospective multi-center international observational registry[J]. Int J Cardiol,2014,171:209-216.
相似文献/References:
[1]韩雅君,朱慧,王丽媛,等.虚拟组织学对急性冠状动脉综合征患者斑块评价研究进展[J].心血管病学进展,2015,(5):641.[doi:10.3969/j.issn.1004-3934.2015.05.031]
HAN Yajun,ZHU Hui,WANG Liyuan,et al.Evaluating Plaque in Patients with Acute Coronary Syndrome by Intravascular
Ultrasound with Virtual Histology[J].Advances in Cardiovascular Diseases,2015,(6):641.[doi:10.3969/j.issn.1004-3934.2015.05.031]
[2]魏恒争,木胡牙提.比伐卢定在急性冠状动脉综合征患者PCI中的应用进展[J].心血管病学进展,2015,(6):725.[doi:10.3969/j.issn.1004-3934.2015.06.017]
WEI Hengzheng,MUHU Yati.Advance in Research of Bivalirudin During Percutaneous Coronary Intervention
in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2015,(6):725.[doi:10.3969/j.issn.1004-3934.2015.06.017]
[3]丁晓彤 张欣 左海奇 孙雨萌 贾赫 刘宏伟 孙鑫 孙延明 王岚峰 王姝.应激性心肌病诊治进展[J].心血管病学进展,2019,(5):778.[doi:10.16806/j.cnki.issn.1004-3934. 2019.05.028]
DING Xiaotong,ZHANG Xin,ZUO Haiqi,et al.Diagnosis and Treatment of Takotsubo Sydrome[J].Advances in Cardiovascular Diseases,2019,(6):778.[doi:10.16806/j.cnki.issn.1004-3934. 2019.05.028]
[4]白斯特 潘建华 蔡梦珊 姜馨.白介素-1家族在急性冠状动脉综合征发生和发展过程中的机制及治疗现状进展[J].心血管病学进展,2022,(1):64.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.017]
BAI Site,PAN Jianhua,CAI Mengshan,et al.Mechanism and Treatment Status of Interleukin-1 Family in Occurrence and Development of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2022,(6):64.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.017]
[5]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(6):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]